Skip to main content
Erschienen in: Journal of Infection and Chemotherapy 6/2011

01.12.2011 | Original Article

Usefulness of presepsin (sCD14-ST) measurements as a marker for the diagnosis and severity of sepsis that satisfied diagnostic criteria of systemic inflammatory response syndrome

verfasst von: Tatsuyori Shozushima, Gaku Takahashi, Naoya Matsumoto, Masahiro Kojika, Yoshikazu Okamura, Shigeatsu Endo

Erschienen in: Journal of Infection and Chemotherapy | Ausgabe 6/2011

Einloggen, um Zugang zu erhalten

Abstract

CD14 is present in macrophage, monocyte, and granulocyte cells and their cell membranes, and it is said to be responsible for intracellular transduction of endotoxin signals. Its soluble fraction is present in blood and is thought to be produced in association with infections. It is called the soluble CD14-subtype (sCD14-ST), and in the following text it is referred to by its generic name, presepsin. We have previously reported that presepsin is produced in association with infection and that it is specifically expressed in sepsis. In the present study we developed a new rapid diagnostic method by using a chemiluminescent enzyme immunoassay that allowed making automated measurements in a shorter time. The results of using this method to measure presepsin values in different pathological conditions were normal, 294.2 ± 121.4 pg/ml; local infection, 721.0 ± 611.3 pg/ml; systemic inflammatory response syndrome, 333.5 ± 130.6 pg/ml; sepsis, 817.9 ± 572.7 pg/ml; and severe sepsis, 1,992.9 ± 1509.2 pg/ml; the presepsin values were significantly higher in patients with local infection, sepsis, and severe sepsis than in patients who did not have infection as a complication. In a comparative study with other diagnostic markers of sepsis based on ROC curves, the area under the curve (AUC) of presepsin was 0.845, and greater than the AUC of procalcitonin (PCT, 0.652), C-reactive protein (CRP, 0.815), or interleukin 6 (IL-6, 0.672). In addition, a significant correlation was found between the APACHE II scores, an index of disease severity, and the presepsin values, suggesting that presepsin values can serve as a parameter that closely reflects the pathology.
Literatur
1.
Zurück zum Zitat Endo S, Sato N, Kasai T, Suzuki Y, Kojika M, Takahashi G, et al. Assessment of serum procalcitonin levels by immunochromatography: its significance as a rapid diagnostic technique for sepsis. Jpn J Crit Care Endotoxemia 2007;11:186–195 (in Japanese). Endo S, Sato N, Kasai T, Suzuki Y, Kojika M, Takahashi G, et al. Assessment of serum procalcitonin levels by immunochromatography: its significance as a rapid diagnostic technique for sepsis. Jpn J Crit Care Endotoxemia 2007;11:186–195 (in Japanese).
2.
Zurück zum Zitat Endo S, Yaegashi Y, Sato N, Suzuki Y, Ogawa M, Kojika M, et al. Comparative study of soluble CD14 and soluble CD14-subtype in sepsis. Med Postgrad. 2006;44:381–5. Endo S, Yaegashi Y, Sato N, Suzuki Y, Ogawa M, Kojika M, et al. Comparative study of soluble CD14 and soluble CD14-subtype in sepsis. Med Postgrad. 2006;44:381–5.
3.
Zurück zum Zitat Endo S, Yaegashi Y, Sato N, Kojika M, Suzuki Y, Shirakawa K, et al. Usefulness of soluble CD14 subtype which as is a new diagnostic marker for sepsis. Jpn J Crit Care Endotoxemia 2005;9:46–950 (in Japanese). Endo S, Yaegashi Y, Sato N, Kojika M, Suzuki Y, Shirakawa K, et al. Usefulness of soluble CD14 subtype which as is a new diagnostic marker for sepsis. Jpn J Crit Care Endotoxemia 2005;9:46–950 (in Japanese).
4.
Zurück zum Zitat Miyata M, Sato N, Takahashi G, Takahashi M, Endo S, Shirakawa K, et al. The utility of the soluble CD-14-subtype for diagnosis of sepsis, the examination of the simple diagnostic kit. J Iwate Med Assoc. 2007;59:325–31. Miyata M, Sato N, Takahashi G, Takahashi M, Endo S, Shirakawa K, et al. The utility of the soluble CD-14-subtype for diagnosis of sepsis, the examination of the simple diagnostic kit. J Iwate Med Assoc. 2007;59:325–31.
5.
Zurück zum Zitat Yaegashi Y, Shirakawa K, Sato N, Suzuki Y, Kojika M, Endo S, et al. Evaluation of a newly identified soluble CD14 subtype as a marker for sepsis. J Infect Chemother. 2005;11:234–8.PubMedCrossRef Yaegashi Y, Shirakawa K, Sato N, Suzuki Y, Kojika M, Endo S, et al. Evaluation of a newly identified soluble CD14 subtype as a marker for sepsis. J Infect Chemother. 2005;11:234–8.PubMedCrossRef
6.
Zurück zum Zitat ACCP/SCCM Consensus Conference Committee. Definitions for sepsis and organ failure and guidelines for use of innovate therapies in sepsis. Crit Care Med 1992;20:867–874. ACCP/SCCM Consensus Conference Committee. Definitions for sepsis and organ failure and guidelines for use of innovate therapies in sepsis. Crit Care Med 1992;20:867–874.
7.
Zurück zum Zitat Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med. 1985;13:818–29.PubMedCrossRef Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med. 1985;13:818–29.PubMedCrossRef
8.
Zurück zum Zitat Kurihara T, Yanagida A, Yokoi H, Koyata A, Matsuya T, Ogawa J, et al. Evaluation of cardiac assays on a benchtop chemiluminescent enzyme immunoassay analyzer, PATHFAST. Anal Biochem 2008;375(1):144–146. Kurihara T, Yanagida A, Yokoi H, Koyata A, Matsuya T, Ogawa J, et al. Evaluation of cardiac assays on a benchtop chemiluminescent enzyme immunoassay analyzer, PATHFAST. Anal Biochem 2008;375(1):144–146.
Metadaten
Titel
Usefulness of presepsin (sCD14-ST) measurements as a marker for the diagnosis and severity of sepsis that satisfied diagnostic criteria of systemic inflammatory response syndrome
verfasst von
Tatsuyori Shozushima
Gaku Takahashi
Naoya Matsumoto
Masahiro Kojika
Yoshikazu Okamura
Shigeatsu Endo
Publikationsdatum
01.12.2011
Verlag
Springer Japan
Erschienen in
Journal of Infection and Chemotherapy / Ausgabe 6/2011
Print ISSN: 1341-321X
Elektronische ISSN: 1437-7780
DOI
https://doi.org/10.1007/s10156-011-0254-x

Weitere Artikel der Ausgabe 6/2011

Journal of Infection and Chemotherapy 6/2011 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.